Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report

We describe the case of a 44-year-old female patient on rituximab for the treatment of multiple sclerosis with undetectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG specific antibodies 18 days after the second dose of SARS-CoV-2 vaccine. Interferon-gamma release assay testing...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Jessica, Murugesan, Kanagavel, Banaei, Niaz, Liu, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243639/
https://www.ncbi.nlm.nih.gov/pubmed/34216738
http://dx.doi.org/10.1016/j.ijid.2021.06.054
_version_ 1783715786547789824
author Ferguson, Jessica
Murugesan, Kanagavel
Banaei, Niaz
Liu, Anne
author_facet Ferguson, Jessica
Murugesan, Kanagavel
Banaei, Niaz
Liu, Anne
author_sort Ferguson, Jessica
collection PubMed
description We describe the case of a 44-year-old female patient on rituximab for the treatment of multiple sclerosis with undetectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG specific antibodies 18 days after the second dose of SARS-CoV-2 vaccine. Interferon-gamma release assay testing for SARS-CoV-2 was positive on day 19, demonstrating a robust T cell-mediated response despite the lack of an antibody-mediated response.
format Online
Article
Text
id pubmed-8243639
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-82436392021-07-01 Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report Ferguson, Jessica Murugesan, Kanagavel Banaei, Niaz Liu, Anne Int J Infect Dis Article We describe the case of a 44-year-old female patient on rituximab for the treatment of multiple sclerosis with undetectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG specific antibodies 18 days after the second dose of SARS-CoV-2 vaccine. Interferon-gamma release assay testing for SARS-CoV-2 was positive on day 19, demonstrating a robust T cell-mediated response despite the lack of an antibody-mediated response. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-06-30 /pmc/articles/PMC8243639/ /pubmed/34216738 http://dx.doi.org/10.1016/j.ijid.2021.06.054 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ferguson, Jessica
Murugesan, Kanagavel
Banaei, Niaz
Liu, Anne
Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
title Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
title_full Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
title_fullStr Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
title_full_unstemmed Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
title_short Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
title_sort interferon-gamma release assay testing to assess covid-19 vaccination response in a sars-cov-2 seronegative patient on rituximab: a case report
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243639/
https://www.ncbi.nlm.nih.gov/pubmed/34216738
http://dx.doi.org/10.1016/j.ijid.2021.06.054
work_keys_str_mv AT fergusonjessica interferongammareleaseassaytestingtoassesscovid19vaccinationresponseinasarscov2seronegativepatientonrituximabacasereport
AT murugesankanagavel interferongammareleaseassaytestingtoassesscovid19vaccinationresponseinasarscov2seronegativepatientonrituximabacasereport
AT banaeiniaz interferongammareleaseassaytestingtoassesscovid19vaccinationresponseinasarscov2seronegativepatientonrituximabacasereport
AT liuanne interferongammareleaseassaytestingtoassesscovid19vaccinationresponseinasarscov2seronegativepatientonrituximabacasereport

Ejemplares similares